High expression of somatostatin receptors and messenger ribonucleic acid for its receptor rubtypes in organ-confined and locally advanced human prostate cancers

Journal of Clinical Endocrinology and Metabolism

Volumn 85, Issue 7, 2000, Pages 2564-2571

  Halmos, Gabor ^a   Schally, Andrew V ^a   Sun, Baodong ^a   Davis, Rodney ^b   Bostwick, David G ^c   Plonowski, Artur ^a,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

^d MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; MEMBRANE PROTEIN; RECEPTOR SUBTYPE; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; VAPREOTIDE;

ADULT; AGED; ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER GRADING; CANCER RECURRENCE; CONTROLLED STUDY; DISSOCIATION CONSTANT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; RECEPTOR BINDING; RECEPTOR DENSITY; SCORING SYSTEM;

AGED; AGED, 80 AND OVER; CELL MEMBRANE; HUMANS; MALE; MIDDLE AGED; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOLIGAND ASSAY; RECEPTORS, SOMATOSTATIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 0034457915     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.85.7.2564     Document Type: Article

References (45)

1. Cancer statistics
2. The role of increasing detection in the rising incidence of prostate cancer
3. Radical prostatectomy for pathological stage C prostate cancer: Influence of pathological variables and adjuvant treatment on disease outcome
4. Conservative management with symptomatic treatment and delayed hormonal manipulation is justified in men with locally advanced carcinoma of the prostate
5. Postoperative radiation for pathological stage C prostate cancer
6. A multivariative analysis of clinical and pathological factors which predict for prostate-specific antigen failure after radical prostatectomy after prostate cancer
7. Radical prostatectomy and postoperative irradiation in patients with pathological stage C (T3) carcinoma pf the prostate
8. Hypothalamic and other peptide hormones
9. Mechanisms of antineoplastic action of somatostatin analogs
10. Oncological applications of somatostatin analogues
11. Somatostatin analogs for diagnosis and treatment of cancer
12. Somatostatin receptor scintigraphy
13. Radiolabeled somatostatin analogs in prostate cancer
14. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors
15. Detection of somatostatin receptor subtype 2 (SSTR2) in established tumors and tumor cell lines: Evidence for SSTR2 heterogeneity
16. Evaluation of receptors for somatostatin in various tumors using different analogs
17. Expression of somatostatin receptors in human prostatic cell lines
18. Somatostatin analog RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of androgen-independent DU-145 human prostate cancer line in nude mice
19. Effects of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PC-3 human prostate-cancer xenografts in nude mice
20. 188Re-RC-160, a directly labeled somatostatin analog
21. Somatostatin receptors in human prostate and prostate cancer
22. 1]-octreotide scintigraphy
23. Different expression patterns of somatostatin receptor subtypes in cultured epithelial cells from human normal prostate and prostate cancer
24. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on growth of the androgen-independent dunning R-3327-AT-1 rat prostate cancer
25. Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen- independent dunning R-3327-AT-1 prostate cancer in rats at non-toxic doses
26. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238
27. Response to administration of somatostatin analog RC-160 (Vapreotide) in patients with advanced prostate at relapse time
28. Characterization of bombesin/gastrin-releasing peptide receptors in human breast cancer and their relationship to steroid receptor expression
29. Somatostatin receptor expression in lung cancer
30. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
31. Somatostatin receptors
32. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms
33. Analysis of somatostatin receptor subtype mRNA expression in human breast cancer
34. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: Mediation by human somatostatin receptor subtypes SSTR1 and SSTR2
35. mRNA phenotyping of the major ligands and receptors of the EGF superfamily in human ovarian epithelial cells
36. A versatile computerized approach for characterization of ligand binding systems
37. The attraction of proteins for small molecules and ions
38. 3]-octreotide: The Rotterdam experience with more than 1000 patients
39. Yttrium-90-labeled somatostatin-analogue for cancer treatment
40. Somatostatin analogues for somatostatin-receptor-mediated radiotherapy of cancer
41. Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues
42. Direct inhibitory effect of somatostatin on the growth of the human prostatic cancer cell line LNCaP: Possible mechanism of action
43. Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5
44. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor
45. A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer